XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial showed that rivaroxaban...

Descripción completa

Detalles Bibliográficos
Autores principales: Camm, A John, Amarenco, Pierre, Haas, Sylvia, Hess, Susanne, Kirchhof, Paulus, van Eickels, Martin, Turpie, Alexander GG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108256/
https://www.ncbi.nlm.nih.gov/pubmed/25083135
http://dx.doi.org/10.2147/VHRM.S63298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108256/
https://www.ncbi.nlm.nih.gov/pubmed/25083135
http://dx.doi.org/10.2147/VHRM.S63298

Ejemplares similares